Details

PREFACE ix <p>CONTRIBUTORS xi</p> <p><b>PART I FUNDAMENTAL CONCEPTS 1</b></p> <p>1. Current Needs for New Therapeutic Agents and Discovery Strategies—A Systems Pharmacology Approach 3<br /> <i>Sophie C. Desbiens and David H. Farb</i></p> <p>2. Target Selection in Drug Discovery 25<br /> <i>Charles F. Albright</i></p> <p>3. New Drug Applications 35<br /> <i>John S. McInnes and Donald O. Beers</i></p> <p>4. From Concept to the Clinics: Development of Cancer Therapeutics 47<br /> <i>Balveen Kaur, Gregory B. Lesinski, and Abhik Ray Chaudhary</i></p> <p>5. Development of Countermeasures for Bioterrorism in the United States 73<br /> <i>Gregory H. Levine and Jeffrey I. Handwerker</i></p> <p>6. Development and Application of Conformation-Selective Integrin Antibodies 91<br /> <i>Nathan S. Astrof, Dan Peer, and Motomu Shimaoka</i></p> <p>7. Pain Management Market Overview 113<br /> <i>Anita Holdcroft</i></p> <p>8. Antiviral Market Overview 127<br /> <i>Anita Arora, Natalia Mendoza, and Stephen K. Tyring</i></p> <p><b>PART II METHODS AND TECHNIQUES IN DRUG DISCOVERY AND DEVELOPMENT 145</b></p> <p>9. High-Throughput Screening for Small-Molecule Drug Discovery 147<br /> <i>C. Parker and J.-H. Zhang</i></p> <p>10. Mass Spectrometry 181<br /> <i>Robert D. English and Anthony M. Haag</i></p> <p>11. Molecular Screening for Therapeutic Agents 207<br /> <i>R. Damoiseaux</i></p> <p>12. Accelerator Mass Spectrometry and Positron Emission Tomography in Human Microdosing 241<br /> <i>Zhengdong Cheng</i></p> <p>13. Development of Antimicrobial Peptides as Therapeutic Agents 285<br /> <i>Robert S. Hodges, Ziqing Jiang, James Whitehurst, and Colin T. Mant</i></p> <p>14. Antibodies for Human Diseases 359<br /> <i>Guo-Liang Yu and Jian Ni</i></p> <p>15. Combinatorial Compounds and Drug Discovery 399<br /> <i>James C. Bigelow</i></p> <p>16. Locoregional Chemoradiotherapy of Cancer Using Hydrogel 413<br /> <i>David J. Yang, Ali Azhdarinia, Hiroaki Kurihara, and E. Edmund Kim</i></p> <p>17. RNAi-Mediated Therapeutics 425<br /> <i>Nuria Morral and Scott R. Witting</i></p> <p>18. Crystallography 445<br /> <i>Carl H. Schwalbe</i></p> <p>19. PEGylation 463<br /> <i>Sanju Dhawan, Deepak N. Kapoor, Rishi Kapil, Mano Kumarj, and Ankur Bansal</i></p> <p>20. Gold Standard Animal Models 517<br /> <i>Carol Casteneda and Michael S. LaPointe</i></p> <p>21. Discovery of Vaccine Adjuvants 533<br /> <i>Fiona A. Sharp and Ed C. Lavelle</i></p> <p>22. Oral Delivery of Macromolecules for the Development of Therapeutic Agents 547<br /> <i>Hye J. Lee and Chanmi Choi</i></p> <p>23. Aerosol Drug Delivery to the Lungs 565<br /> <i>Andrew R. Martin and Warren H. Finlay</i></p> <p>24. Resistance to Antiplatelet Theraphy 589<br /> <i>Paul A. Gurbel, Udaya S. Tantry, and Mark J. Antonino</i></p> <p>25. Antibiotic Development 611<br /> <i>Robert L. Bettiker and Jason C. Gallagher</i></p> <p><b>PART III THERAPEUTIC TOPICS 629</b></p> <p>26. Antimicrobial Resistance in Biofi lms: A Sticky Situation 631<br /> <i>Shu Yeong Queck and Michael Otto</i></p> <p>27. Drotrecogin Alfa Activated (Recombinant Human Activated Protein C, Xigris) 645<br /> <i>Byungse Suh and Rafi k Samuel</i></p> <p>28. Anti-Inflammatory Therapeutics 655<br /> <i>Marion M. Chan and Dunne Fong</i></p> <p>29. Anti-Inflammatory/Analgesics: An In-depth Look at p38 MAP Kinases 673<br /> <i>Kelly L. Brown</i></p> <p>30. Cardiovascular Disease: In-Depth Look 707<br /> <i>Nicholas B. Norgard and Mazen Abu-Fadel</i></p> <p>31. Ezetimibe and Cholesterol Absorption 723<br /> <i>Stefan Oswald and Werner Siegmund</i></p> <p>32. Cardiology—In-Depth Look: Kinases as Therapeutic Targets in the Heart 743<br /> <i>Karin Mauer and J. Emilio Exaire</i></p> <p>33. Statins in the Reduction of Cardiovascular Events 773<br /> <i>Rajesh Sachdeva, Bradley Hughes, and Jawahar L. Mehta</i></p> <p>34. Cardiology—In-Depth Look: Advances in Antiplatelet Theraphy 785<br /> <i>Karin Mauer and Jorge F. Saucedo</i></p> <p>35. Gastrointestinal Disorders: A Focus on Acid-Suppressive Agents 813<br /> <i>Brian Hemstreet</i></p> <p>36. Pharmacology of Vasopressin and the Renin—Angiotension—Aldosterone System 825<br /> <i>Elizabeth J. Brant and Julian L. Seifter</i></p> <p>37. New Drugs and Nutaceutical in the Treatment of Osteoarthristis 847<br /> <i>Y. Henrotin and J. Y. Reginster</i></p> <p>38. Development of Anticytokine Agents for Rheumatoid Arthritis 881<br /> <i>Jonathan Sherlock, Christopher D. Buckley, and Karim Raza</i></p> <p>39. Overview of CNS Neuropharmaceuticals 897<br /> <i>Tauser Roxana-Georgiana and Antohe Dan-Stefan</i></p> <p>40. Thinking Outside the Box in Alzheimer Disease Treatment 929<br /> <i>Rudy J. Castellani, Michael W. Marlatt, Akihiko Nunomura, Paula I. Moreira, Hyoung-Gon Lee, Gemma Casadesus, Xiogwei Zhu, George Perry, and Mark A, Smith</i></p> <p>41. Neurotrophic Factors as Novel Therapeutic Targets 943<br /> <i>Stephen D. Skaper</i></p> <p>42. Oncology 963<br /> <i>Arkadiusz Z. Dudek and Steven F. Powell</i></p> <p>43. Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia 999<br /> <i>Muhammad Mansoor Alam and Moshe Talpaz</i></p> <p>44. Aromatase Inhibitors for Breast Cancer 1011<br /> <i>Akm Hossain and Jame Abraham</i></p> <p>45. Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development 1019<br /> <i>Gregory T. Wurz and Michael W. DeGregorio</i></p> <p>46. In-Depth Look: anti-TNF-α Therapies 1045<br /> <i>Satadal Chatterjee and Shobhan Gaddameedhi</i></p> <p>47. Development of Therapeutic Agents: The Maternal—Fetal Perspective 1093<br /> <i>C. Gedeon, F. Garcia Bournissen and G. Koren</i></p> <p>48. History of Antipsychotic Drug Development 1111<br /> <i>Shankar S. Gollapudi and Rajan Radhakrishnan</i></p> <p>49. Radiopharmaceuticals and Medical Imaging: Development of Radioimmumoconjugates for Radioimmunoimaging and Radioimmunotherapy of Malignant Diseases 1137<br /> <i>Gang Niu and Xiaoyuan Chen</i></p> <p>50. Therapeutic Drug Development for Kidney Diseases 1159<br /> <i>Mitchell H. Rosner, Joshua King, and Peter Monteleone</i></p> <p>51. Targeting Chemokines and Angiogenesis in Arthritis 1185<br /> <i>Zoltan Szekaneez and Alisa E Koch</i></p> <p>52. Development of Therapeutic Agents: Methods and Approaches in the Development of Vaccines against Protozoan Parasites 1207<br /> <i>Catherine Ivory and Kris Chadee</i></p> <p>53. Toxicology 1221<br /> <i>John H. Duffus</i></p> <p>54. The Development of Phosphodiesterase 4 Inhibitors for Allergic and Nonallergic Infl ammatory Diseases of the Airways 1233<br /> <i>Mark A. Giembycz</i></p> <p>INDEX 1251</p>

<p>“The text is well-written and includes extensive references.”  (<i>Book News</i>, 1 April 2012)</p>

<b>SHAYNE COX GAD</b>, PhD, DABT, ATS, is the Principal of Gad Consulting Services. He has more than thirty years of experience as a toxicologist, statistical consultant, manager, and consultant on research and development in the chemical, consumer product, contract testing, biotechnology, medical device, and pharmaceutical industries. He is the author of forty-two books and numerous papers, presentations, and other publications.

<b>A comprehensive look at current drug discovery and development methods—and the roadmap for the future</b> <p>Providing both understanding and guidance in characterizing potential drugs and their production and synthesis, <i>Development of Therapeutic Agents Handbook</i> gives professionals a basic tool to facilitate research and development within this challenging process. This comprehensive text brings together, in one resource, a compendium of concepts, approaches, methodologies, and limitations that need to be considered in the formulation of therapeutic agents across a range of therapeutic fields. Both a reference and a call to action for the pharmaceutical industry, <i>Development of Therapeutic Agents Handbook</i> examines recent innovations taking shape in the various medical disciplines involved in drug discovery, and shows why these advances need to be embraced universally among researchers to improve their solution strategies. Additional subject matter includes:</p> <ul> <li> <p>Extensive coverage and in-depth look into novel treatments and therapeutics</p> </li> <li> <p>Discussion of hot topics like new drugs and nutraceuticals, the discovery and development of vaccines, cancer therapeutics, and market overviews</p> </li> <li> <p>Coverage of therapeutic drug development for specific disease areas, such as cardiology, oncology, breast cancer, and kidney diseases</p> </li> </ul> <p>As research in biology, chemistry, medicine, and technology rapidly progresses, it is becoming increasingly important for medical researchers to maintain an up-to-date knowledge base of emerging trends directing promising new therapies. <i>Development of Therapeutic Agents Handbook</i> serves this purpose, acting as both a one-stop reference rich in valid science, and a tool to carve out new pathways in the pursuit of bringing safer and more effective drugs to the marketplace.</p>

US